No abstract

Peste des petits ruminants virus (PPRV, species: small ruminant morbillivirus) is the causative agent of the eponymous notifiable disease, the peste des petits ruminants (PPR) in wild and domestic sheep and goats. Mortality rates vary between 50% and 100%, causing significant losses of estimated 1.5 to 2 billion US Dollars per year. Live-attenuated PPRV vaccine strains are used in the field for disease prevention, but the application of a more thermostable vaccine enabling differentiation between infected and vaccinated animals (DIVA) would be highly desirable to achieve the goal of global disease eradication. We generated a recombinant Newcastle disease virus (rNDV) based on the live-attenuated NDV Clone 30 that expresses the surface protein hemagglutinin (H) of PPRV strain Kurdistan/11 (rNDV_HKur). In vitro analyses confirmed transgene expression as well as virus replication in avian, caprine, and ovine cells. Two consecutive subcutaneous vaccinations of German domestic goats with rNDV_HKur prevented clinical signs and hematogenic dissemination after an intranasal challenge with virulent PPRV Kurdistan/11. Virus shedding by different routes was reduced to a similar extent as after vaccination with the live-attenuated PPRV strain Nigeria 75/1. Goats that were either not vaccinated or inoculated with parental rNDV were used as controls. In summary, we demonstrate in a proof-of-concept study that an NDV vectored vaccine can protect against PPR. Furthermore, it provides DIVA-applicability and a high thermal tolerance.

No abstract

No abstract

No abstract

Highly pathogenic avian influenza virus (HPAIV) belongs to the Orthomyxoviridae family and causes a systemic and highly lethal disease in poultry. Vaccination with recombinant Newcastle disease vector viruses (NDV) expressing the hemagglutinin (HA) of HPAIV H5N1 induces high antibody titers in chickens free of specific pathogens, conveying protection against a lethal infection with HPAIV H5N1. Protection of chickens possessing maternally derived NDV immunity was achieved after the replacement of the surface proteins of NDV, the fusion protein (F), and the hemagglutinin-neuraminidase protein (HN) against those of avian paramyxovirus serotype 8. However, maternal AIV antibodies (αAIV-MDA+) still interfere with vaccine virus replication, resulting in inefficient protection. For our study, recombinant rNDVsolH5_H5 was generated. The insertion of a transgene encoding a truncated soluble HA between the NDV phosphoprotein and matrix protein genes—in addition to the gene encoding a membrane-bound HA inserted between the NDV, F and HN of the lentogenic NDV Clone 30 —was expected to increase the total amount of HA expressed by the recombinant virus. Western blot and mass spectrometry analyses confirmed the increase in HA expression compared to the parental rNDVH5 expressing only the full-length HA. The protective efficacy of the newly generated recombinant NDV was tested in an animal experiment. αAIV-MDA+ chickens were vaccinated either 7, 14, or 21 days after hatching. A homologous challenge infection was carried out three weeks later. Although the youngest chickens showed the highest titer of αAIV-MDA, there were no AIV antibodies detectable 21 days after vaccination. However, 40% of vaccinated chickens were protected, while 85% and 100% protection was observed in the middle-aged and oldest chickens, which had low and no detectable levels of αAIV-MDA, and moderate and high AIV antibody levels after vaccination, respectively. Challenge infection of non-vaccinated chickens resulted in high mortality.

No abstract